Home
Solutions
Products
Pricing
Resources
Request Demo
Start Free
Menu Search Account

LegiStorm

Get LegiStorm App Visit Product Demo Website
» Get LegiStorm App
» Get LegiStorm Pro Free Demo
StateStorm

Weekly Updates

LegiStorm is constantly adding new information on the people, places and reports in our database. In the past week, LegiStorm added:

  • 1315 new people
  • 107 new organizations
  • 1149 new photos
  • 1999 job history records for people in our database
  • 713 education records for people in our database
  • 3184 contact addresses, emails and URLs (LinkedIn, Facebook, etc.)
  • 1 new person through the revolving door
  • 132 new policy reports
  • 15 new trips to our privately funded travel database
  • 356 new personal financial disclosures
  • 9208 new press releases
  • 5 new town halls
  • 37 new hearings

Caught Our Eye Rss

» More from Caught Our Eye
» More from our DevBlog

Government Operations: Changes in FDA Structure

  Premium   Download PDF Now (12 pages)
Report Type Reports and Testimonies
Report Date Dec. 8, 1995
Report No. HEHS-96-53R
Subject
Summary:

Pursuant to a congressional request, GAO examined changes in the Food and Drug Administration's (FDA) organizational structure since the new commissioner was appointed, focusing on changes in: (1) the number of staff positions in the Office of the Commissioner, staff offices, and product centers; and (2) FDA decisionmaking authority. GAO noted that between 1990 and 1995: (1) FDA increased its total staff by 20 percent; (2) the Office of the Commissioner received 4 percent of the staff increase, while staff offices received 11 percent and product centers received 85 percent of the increase; (3) the number of full-time equivalent (FTE) staff in the commissioner's office increased by 84 percent, while the number of staff reporting directly to the commissioner decreased; (4) FTE in staff offices increased by 21 percent, while FTE in product centers stayed about the same; and (5) there was no change in direction regarding the centralization of FDA decisionmaking authority, but some organizational changes decentralized product approval and centralized functions such as policy development.

« Return to search Government Accountability Office reports

HomeAbout Us Contact UsPrivacy PolicyTerms of UseJoin Us
© LegiStorm
LegiStorm
2101 L St. NW, Suite 300
Washington, DC 20037
(202) 360-4172 / congress@legistorm.com